

AD _____

Award Number: DAMD17-03-1-0085

TITLE: Development of Novel Bifunctional Compounds that Induce Apoptosis in Prostate Cancer Cells

PRINCIPAL INVESTIGATOR: John M. Essigmann, Ph.D.

CONTRACTING ORGANIZATION: Massachusetts Institute of Technology
Cambridge, Massachusetts 02139

REPORT DATE: February 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050824 121

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE February 2005	3. REPORT TYPE AND DATES COVERED Annual (1 Feb 2004 - 31 Jan 2005)	
4. TITLE AND SUBTITLE Development of Novel Bifunctional Compounds that Induce Apoptosis in Prostate Cancer Cells			5. FUNDING NUMBERS DAMD17-03-1-0085	
6. AUTHOR(S) John M. Essigmann, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Massachusetts Institute of Technology Cambridge, Massachusetts 02139 E-Mail: jessig@mit.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) We have designed and synthesized a novel compound (11 β) that efficiently triggers apoptosis in prostate cancer cells such as LNCaP. This bifunctional compound was designed to form DNA adducts that are camouflaged by the androgen receptor making them less readily repaired in AR+ prostate cancer cells. The aims of our studies are to investigate the mechanisms by which 11 β is able to trigger apoptosis in target cells. One approach we are taking is to prepare structural analogs of 11 β that have increased or decreased abilities to cause apoptosis in LNCaP cells. Methods have been developed that will permit us to determine the fates of 11 β -DNA adducts in treated cells as well as in target and nontarget tissues in xenograft mouse models of human prostate cancer. Another objective is to identify the signaling events that lead from DNA adducts to activation of the apoptotic program. Finally we have obtained encouraging results from animal experiments that indicate that molecules such as 11 β may have clinical potential for the treatment of human tumors.				
14. SUBJECT TERMS Chemotherapy, DNA damage and repair, apoptosis, steroid receptors				15. NUMBER OF PAGES 11
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4-8
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	10
References.....	11
Appendices.....	11

INTRODUCTION

The objective of our research is to develop more effective therapeutics for the treatment of prostate cancers. One novel bifunctional compound (**11 β**) that we have prepared rapidly induces apoptosis in several prostate cancer cell lines in vitro. The **11 β** compound contains a chemically reactive nitrogen mustard linked to a steroid moiety that binds with high affinity to the androgen and progesterone receptor proteins. This compound was designed to create DNA adducts that form tight complexes with these steroid receptors that make the adducts difficult to repair in prostate cancer cells. Preliminary studies of **11 β** in cell culture indicated that its effects on prostate cancer cells were different from those of other alkylating agents used in chemotherapy. The apoptotic responses of prostate cancer cells suggested that the **11 β** compound might be a useful agent for chemotherapy. The Specific Aims of our research are to understand the fate of **11 β** -DNA adducts in treated cells and investigate the mechanisms that lead to apoptosis. We also proposed experiments to assess the antitumor potential of **11 β** in animal models of human prostate cancer.

BODY

Task 1: *Chemical synthesis of monochloro and 17 α -methyl analogs of our lead compound, 11 β -(17 α OH-estradien-4(5),9(10)-3-one)-C6NC2-mustard (**11 β**), and assessment of their toxicity in prostate cancer cells in vitro.*

The chemical synthesis of the monochloro and 17 α -methyl analogs that were the initial focus of this task has been completed as described in the FY 2004 Progress Report.


During the last year we studied the responses of LNCaP prostate cancer cells to both the monochloro and 17 α -methyl analogs. The outcomes of our structure-activity studies have identified several features of the active **11 β** compound responsible for its ability to induce apoptosis in resistant prostate cancer cell lines. We initially focused our investigations on structure-activity relationships of the reactive N,N-bis-(2-chloroethyl)-aniline. Because it has two 2-chloroethyl groups **11 β** can form monoadducts, intra- and inter-strand crosslinks. Substitution of one or both chlorine atoms by methoxyl groups produced **11 β** analogs that were either unreactive (i.e., both chlorines replaced) or had a single reactive 2-chloroethyl group (i.e. one chlorine replaced) that could only form monoadducts. Investigation of the cytotoxic effects of these analogs revealed that the apoptotic response depends absolutely on the presence of both of the 2-chloroethyl groups in **11 β** – implying that apoptosis requires the formation of intra- or inter-strand crosslinks. It is clear, however, that features other than the N,N-bis-(2-chloroethyl)-aniline moiety in **11 β** are essential, because chlorambucil and melphalan, both of which have bifunctional aniline mustards, fail to induce apoptosis in LNCaP cells. Our studies led to the conclusion that the ability to form bifunctional adducts that interact with a steroid receptor is key to the ability to induce apoptosis.

As we previously reported, the affinity of 17 α -methyl-**11 β** for the androgen receptor was identical to that of the original 17 α -H-**11 β** compound. Both molecules bound to the AR

with affinities of approximately 25% that of dihydrotestosterone. We speculated that the 17- α methyl 11 β analog would be more potent than the original 17 α -H 11 β because the methyl group would be expected to block the oxidative metabolism of the 17-OH position. Oxidation of the 17-OH to a ketone would significantly reduce affinity for the AR. Contrary to our expectations, the presence of the methyl group had no effect on the biological activities of 11 β . Since preparation of the 17- α methyl 11 β compound requires several additional steps we decided not to investigate it further at this time as the original compound can be made more efficiently for *in vivo* studies.

Task 2: *Determine the fate of 11 β -DNA adducts in prostate cancer cells.*

As described in the FY 2004 Progress Report, began examination of the kinetics of formation and repair of 11 β -DNA adducts in prostate cancer cells using electrospray ionization mass spectrometry (EIMS). The EIMS technique did not prove sensitive enough to accurately quantify DNA adducts in cell culture experiments. We then developed a highly sensitive method for their analysis that is based on the technique of Accelerator Mass Spectrometry (AMS). These experiments have been exceptionally successful in the detection and quantification of 11 β -DNA adducts in DNA isolated from cells in culture as well as from xenograft tumors in mice. A radiolabeled 11 β analog was prepared by modification of its chemical synthesis to allow incorporation of one ^{14}C atom into the linker connecting the steroid and aniline mustard moieties. The sensitivity of the AMS technique – which is up to 7 orders of magnitude greater than conventional liquid scintillation counting – has permitted detection of as little as a few hundred DNA adducts in [^{14}C]11 β -treated cells. In our initial studies with LNCaP cells *in vitro* we examined the relationships between both 11 β concentration and exposure time with the level of DNA adducts. Results based on further refinements of analytical protocols are shown in Figure 1. Increasing levels of 11 β -DNA adducts were detected by AMS analysis of DNA isolated from LNCaP cells treated for various times with 10 μM [^{14}C]-11 β *in vitro*. DNA isolated from approximately 1×10^6 cells was used for each analysis. We have also performed an initial experiment in an animal model. Mice with LNCaP tumors growing as xenografts were treated with 50 mg/kg [^{14}C]-11 β (1 μCi ^{14}C ; specific activity 0.48 mCi/mmol) and DNA isolated from liver and tumor tissues after 4 h. Based on the results of this experiment we are able to detect ~600 11 β -DNA adducts per cell in tumor tissue.



The results of these studies will permit us to: (1) examine the rate of repair of DNA adducts in receptor-positive and -negative cells to test the hypothesis that DNA adducts

concealed by the androgen receptor are less well repaired; and (2) define the quantitative relationship between adduct level and cytotoxic effects to facilitate optimization of dosing protocols in animal studies.

Task 3: *Determine which apoptotic pathways are activated in prostate cancer cells responding to 11 β .*

One aim of these experiments was to uncover the reasons for the ability of 11 β to overcome the resistance of LNCaP and other prostate cancer cells to other alkylating drugs. We began to investigate the pathways and mechanisms that lead to apoptosis by identification of the initiator and effector caspases that are activated by 11 β . Initial experiments found that the pan-caspase inhibitor ZVD.fmk prevented cleavage of PARP confirming that caspase activation was, in fact, triggered in LNCaP cells by 11 β .

The results of our structure-activity studies with and monochloro analog indicated that a specific type of DNA adduct was required for activation of apoptosis. These findings have refocused our investigations on biochemical changes that are more directly related to DNA damage. Our present goal was to investigate the immediate consequences of 11 β -DNA adducts on DNA repair and cell cycle checkpoints – at the beginning of the apoptotic pathways. Thus, we have focused on the immediate consequences of the crosslinks formed by 11 β in LNCaP cells. We have found evidence of activation of the p53 pathway which is consistent with other observations including increased levels of p21. Several sites on p53 can be phosphorylated in response to DNA damage. Phosphorylation at ser15 occurs as soon as 4-8hr after addition of 11 β -dichloro. This phosphorylation is absent when cells are treated with the dimethoxy derivative, indicating that DNA damage is responsible.

We have also looked for phosphorylation of the cell cycle check point kinases Chk-1 and Chk-2. Following addition of 11 β -dichloro to cultures of LNCaP cells, evidence of Chk-1 phosphorylation was seen only after 16hr. Similarly, Chk-2 (thr 68) phosphorylation, was seen after 24hr. The timing of Chk-1 and Chk-2 phosphorylation occurs well after other biochemical changes that commit cells to apoptosis suggesting that the inhibition of these responses by 11 β may be important.

During the next year we shall continue to investigate the responses of p53, Chk-1 and Chk-2 by comparing those of 11 β -dichloro with other compounds. We shall conduct experiments to determine whether the 11 β -monochloro analog or chlorambucil can activate the p53 or Chk pathways LNCaP cells. Discovery of changes in either pathway that are specific to 11 β will direct further studies toward identification of the biochemical basis for this compound's effectiveness.

Task 4: *Assess the efficacy of 11 β in an animal xenograft model of human prostate cancer.*

As reported in our FY 2004 Progress Report, the 11 β compound is very effective in preventing the growth of LNCaP cell in mouse xenografts. It is especially encouraging that the dose of 11 β that was effective in preventing tumor growth did not show significant toxic effects in the animals. During the past year we have sought to optimize the treatment protocol and method of delivery of 11 β to increase the antitumor response.

In our initial investigations of the antitumor activity of 11 β we have administered the compound dissolved in a vehicle containing Cremophor EL, a polyoxyethylated castor oil. The availability of radiolabeled compound enabled us to determine its plasma levels and tissue distribution following i.p. injection. These investigations revealed that 11 β was rapidly absorbed and reached pharmacological concentrations in the blood shortly after administration. The maximum concentration of 11 β in the blood (C_{max}) occurred within 30 min and then declined with a half life of approximately 1.3 h. Some of our pharmacokinetic and biodistribution data are shown in Figure 2. They indicate that delivery of 11 β into the peripheral circulation and tumor tissue was likely limited by its removal from the circulation by the liver and subsequent transport into the intestine/feces. These results pointed to the need for additional investigation of formulation, delivery and dosing schedules that could significantly enhance tumor response.




Figure 2. Distribution of [¹⁴C]-11 β in tissues and blood after i.p. injection.

We have approached this problem by first seeking an improved vehicle in which to administer the compound. One reason for this was that Cremophor EL in our current vehicle poses potential problems of clinically significant side effects including acute hypersensitivity reactions and peripheral neurotoxicity. Another reason is that we believe that a more optimal pharmacokinetic profile for 11 β can be obtained by formulating the compound in a manner that slows its uptake by the liver. Increasing the plasma half life of 11 β would allow us to decrease the total dose required to reach effective concentrations in target tissues and perhaps lower its potential to produce adverse side effects. Recent formulation studies on 11 β in work with the Sasishakran lab here at MIT revealed that the physio-chemical properties of 11 β make it ideal for incorporation into long-circulating PEG-coated liposomes that can evade uptake by the reticulo-endothelial (RE) system. The liposome-based formulations of other hydrophobic anticancer drugs such as doxorubicin and paclitaxel are reported to be effective and have fewer adverse side effects formulations in which these drugs are administered in Cremophor EL or other

vehicles. Selective extravascular accumulation of liposome formulations in tumor xenografts has been reported to result from increased microvascular permeability that is characteristic of vessels in the hypoxic environments of solid tumors. Our initial results are shown in Figure 3 indicate persistence in blood over a 10 h period of the liposome-encapsulated 11 β when injected into the tail vein.




Figure 3. Relative levels of [^{14}C]-11 β in blood after injection of 11 β -liposomes.

During the next year we shall continue to investigate the pharmacokinetics of 11 β in liposomes and assess its delivery to tumor and normal tissues in a xenograft mouse model of prostate cancer using [^{14}C]-11 β . Traditional liquid scintillation counting methods will be used to determine the amount of 11 β in each tissue, while the much more sensitive AMS analysis will be used to quantify 11 β -DNA adducts that are formed in target and nontarget tissues. The measurement of DNA adducts will provide a direct assessment of the amount of biologically active compound reaching the desired molecular target within the tumor and allow us to investigate dosing parameters (e.g., amount, frequency and route of administration). We will also seek to optimize the dose and schedule of administration to enhance the antitumor responses.

KEY RESEARCH ACCOMPLISHMENTS

- Evaluation of toxicity of the monochloro-11 β and 17 α -methyl-11 β compounds. The absence of apoptotic responses in LNCaP cells treated with monochloro-11 β indicated bis-DNA adducts are required for apoptosis.
- Optimization of a sensitive method for the kinetic analysis of DNA adducts formed in cells treated *in vitro* with [¹⁴C]-11 β and application of the method to the identification and quantification 11 β -DNA adducts in xenograft tumors. These results have led to experiments that will define the dose relationship between cytotoxic responses *in vitro* and therapeutic responses in animal models.
- Discovery that the p53 pathway was activated in LNCaP cells by 11 β -dichloro while the Chk-1 and Chk-2 responses are absent. These results have pointed to identify the molecular basis of the apoptotic responses of LNCaP cells to 11 β -dichloro.
- Definition of the pharmacokinetics of 11 β in mice and preliminary formulation of 11 β into liposomes. The liposomal form of 11 β was found to have increased stability and prolonged circulation in blood. This result has prompted investigation of the pharmacokinetics and efficacy of liposomal 11 β as an antitumor agent in mice.

REPORTABLE OUTCOMES

Manuscripts:

John C. Marquis, Shawn M. Hillier, A. Nicole Dinaut, Denise Rodrigues, Kaushik Mitra, John M. Essigmann* and Robert G. Croy*, "A Bis-alkylating DNA Damaging Agent Tethered to a Ligand for the Androgen Receptor Reduces Skp2 Levels and Induces Apoptosis in Prostate Cancer Cells" Submitted February 2005.

Patents applied for:

U.S. Provisional Application No. 60/552,322

TITLE: Methods and Compositions for Treating Cancer
DATE FILED: March 10, 2004
INVENTORS: Essigmann, J.M. and Croy, R.G.

DESCRIPTION OF THE INVENTION: The invention provides methods and compositions for treating cancer. Compounds of the invention can inhibit DNA repair pathways; induce apoptosis; and/or cause cell cycle arrest. Preferred compound of the invention are multifunctional agents that include i) a steroid receptor ligand domain, ii) a

nitrogen mustard domain (that can be inactivated) and iii) a linker that is resistant to hydrolysis under intracellular conditions. Compounds of the invention are useful in treating cancer. Compounds of the invention are useful for treating cancers that do not express or do not over-express a steroid receptor. Compounds of the invention are also useful in treating cancers resistant to DNA damaging compounds because of expression of anti-apoptotic factors (e.g. Bcl-2 and/or Bcl-xl expressing cancers or tumors) on activation of other survival mechanisms (e.g. mutation of PTEN), including mechanisms of apoptosis avoidance or apoptotic resistance. Compounds of the invention are particularly useful for treating prostate cancer that is refractory to treatment with conventional cytotoxic therapies as well as advanced metastatic disease that is resistant to hormonal antagonists.

Degrees Supported:

- Mr. Shawn Hillier has been supported on this grant. He is writing his dissertation and will graduate in June, 2005. Mr. Hillier was responsible for DNA repair, pharmacokinetic and antitumor studies reported in the application.
- Dr. Kaushik Mitra finished his postdoctoral work last year and is working in drug synthesis at Merck and Co. He was part of the synthetic chemistry team.

CONCLUSIONS

We are now engaged in experiments to define the amounts of DNA damage produced by the 11 β compound and the fates of this damage in target and non-target cells in culture and tumor xenografts. This information will help us establish the sequence of events that lead to apoptosis. The results we have obtained in animal models are especially significant. The ability of the 11 β compound to prevent the growth of LNCaP cells in a mouse xenograft model provides evidence of the potential clinical activity of this compound. The activity of 11 β will now be tested in additional xenograft models of human prostate cancer to assess the range of its antitumor properties.

Our research during the next year will focus on two goals: (1) identification of key events that lead to apoptosis in cells treated with 11 β ; and (2) optimizing antitumor responses to 11 β in animal models of prostate cancer. We anticipate that identification of the signaling events originating from DNA adducts will provide clues to the reasons why the 11 β compound is able to trigger apoptosis while other aniline mustard compounds such as chlorambucil do not. We now have sensitive methods to examine the formation of fate of 11 β -DNA adducts in tumors. We will determine the levels of adducts in tumor and normal tissues that lead to antitumor responses and establish correlation with levels of DNA adducts that result in cytotoxic effects on cells in culture. We shall also proceed with the development of a more clinically useful formulation of 11 β .

REFERENCES

None included.

APPENDICIES

None included.